Renhuang Pharmaceuticals Inc. (OTC BB: RHGP) manufactures and distributes a broad line of high-quality nutraceutical, natural medicinal and bio-pharmaceutical products in mainland China. Its three major product lines are Acanthopanax- based natural medicinal products, the Shark Power healthcare series and traditional Chinese medicines.

Renhuang has established a multi-channel research and development infrastructure consisting of in-house researchers, a post-doctoral working center, and collaborations with leading institutions and scientists. The Company has a portfolio of over 100 products, and a presence in more than 50 markets. It has a dominant share of the market for Acanthopanax-based natural medicines and controls 70% of China's Acanthopanax resource (also known as Siberian Ginseng). Products are distributed through a network of over 2,000 sales agents in 24 districts covering over 50% of China and also exported to Russia and Southeast Asia.

The Company acquired Harbin Renhuang Pharmaceutical Company Limited in September 2006 and all of the assets of Qingyang Herbal Extracting Factory in March 2007. The acquired facility is capable of processing approximately 18,000 tons of herbal raw materials into extracts and doubles the Company's current herbal extraction capacity. Renhuang Pharmaceuticals is headquartered in Harbin in the Heilongjiang Province in Northeast China.